Stock Analysis

Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 27%

Despite an already strong run, CVRx, Inc. (NASDAQ:CVRX) shares have been powering on, with a gain of 27% in the last thirty days. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 39% over that time.

Since its price has surged higher, CVRx may be sending strong sell signals at present with a price-to-sales (or "P/S") ratio of 8.7x, when you consider almost half of the companies in the Medical Equipment industry in the United States have P/S ratios under 3.3x and even P/S lower than 1.2x aren't out of the ordinary. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified.

View our latest analysis for CVRx

ps-multiple-vs-industry
NasdaqGS:CVRX Price to Sales Ratio vs Industry January 16th 2025
Advertisement

How CVRx Has Been Performing

Recent times have been advantageous for CVRx as its revenues have been rising faster than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. However, if this isn't the case, investors might get caught out paying too much for the stock.

Want the full picture on analyst estimates for the company? Then our free report on CVRx will help you uncover what's on the horizon.

Is There Enough Revenue Growth Forecasted For CVRx?

In order to justify its P/S ratio, CVRx would need to produce outstanding growth that's well in excess of the industry.

Retrospectively, the last year delivered an exceptional 34% gain to the company's top line. This great performance means it was also able to deliver immense revenue growth over the last three years. Accordingly, shareholders would have been over the moon with those medium-term rates of revenue growth.

Shifting to the future, estimates from the six analysts covering the company suggest revenue should grow by 26% per year over the next three years. Meanwhile, the rest of the industry is forecast to only expand by 9.6% per annum, which is noticeably less attractive.

In light of this, it's understandable that CVRx's P/S sits above the majority of other companies. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

What Does CVRx's P/S Mean For Investors?

Shares in CVRx have seen a strong upwards swing lately, which has really helped boost its P/S figure. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

Our look into CVRx shows that its P/S ratio remains high on the merit of its strong future revenues. At this stage investors feel the potential for a deterioration in revenues is quite remote, justifying the elevated P/S ratio. Unless these conditions change, they will continue to provide strong support to the share price.

You always need to take note of risks, for example - CVRx has 3 warning signs we think you should be aware of.

If you're unsure about the strength of CVRx's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:CVRX

CVRx

A commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.

Excellent balance sheet and overvalued.

Advertisement

Updated Narratives

MA
MarkoVT
5253 logo
MarkoVT on COVER ·

Q3 Outlook modestly optimistic

Fair Value:JP¥1.65k2.0% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
BlackGoat
GOOG logo
BlackGoat on Alphabet ·

Alphabet: The Under-appreciated Compounder Hiding in Plain Sight

Fair Value:US$324.481.3% undervalued
76 users have followed this narrative
3 users have commented on this narrative
1 users have liked this narrative
BE
Bejgal
MNSO logo
Bejgal on MINISO Group Holding ·

MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

Fair Value:US$26.6926.7% undervalued
46 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3405.9% undervalued
136 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative
TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
90 users have followed this narrative
10 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$232.7922.6% undervalued
928 users have followed this narrative
6 users have commented on this narrative
22 users have liked this narrative